Latest Posts
-
Pharma Talks – Interview with Nils Schrader, PhD, Managing Director BIO.North-Rhine-Westfalia (BIO.NRW)
10 March 2026 Question: BIO.NRW sits at the intersection of science, start-ups, industry and policy. In your view, what is still underestimated when it comes to translating excellent science into sustainable biotech companies? Answer: For me, this question has two dimensions. First, what does it actually take to make translation successful? And second, how do…
-
Pharma Talks – Interview with Alan Vanderborght, CEO and founder Kybora
16 December 2025 1. The M&A environment Jens: How would you describe the current state of pharma and biotech M&A? Are we returning to pre-2022 dynamics, or has something fundamentally shifted? Alan: The M&A landscape in biopharma is primarily driven by upcoming losses of exclusivity over the next five to ten years. Big pharma needs…
-
Pharma Talks – Conversation with Frédéric Revah, CEO Genethon
13 November 2025 1. Progress of Genethon’s Gene Therapy Programs Q: How are Genethon’s programs progressing, especially in neuromuscular diseases? A: Genethon is currently advancing a robust pipeline of gene therapy programs with a strong focus on neuromuscular and metabolic disorders. One of the most significant recent achievements is the progression of the Duchenne muscular…